AbbVie (ABBV) EBT Margin Growth (3y) (2015 - 2026)
Analysis
AbbVie (ABBV) EBT Margin Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | -265.00 |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 636.00 |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 3,137.00 |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 625.00 |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -2,179.00 |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 1,494.00 |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -977.00 |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 8,006.00 |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 1,581.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 636.00 |
| Mar 31, 2026 | 304.00 |
| Dec 31, 2025 | -355.00 |
| Sep 30, 2025 | -2,518.00 |
| Jun 30, 2025 | 196.00 |
| Mar 31, 2025 | -2,396.00 |
| Dec 31, 2024 | -4,372.00 |
| Sep 30, 2024 | -1,130.00 |
| Jun 30, 2024 | 651.00 |
| Mar 31, 2024 | -1,547.00 |
| Dec 31, 2023 | 1,935.00 |
| Sep 30, 2023 | -535.00 |
| Jun 30, 2023 | 2,547.00 |
| Mar 31, 2023 | -3,206.00 |
| Dec 31, 2022 | -1,571.00 |
| Sep 30, 2022 | 611.00 |
| Jun 30, 2022 | -166.00 |
| Mar 31, 2022 | 391.00 |
| Dec 31, 2021 | 5,726.00 |
| Sep 30, 2021 | -781.00 |